Existing treatments, such as corticosteroids, immunotherapy, Janus kinase inhibitors, and topical solutions ... the Company’s ability to develop new immunotherapeutic treatments for auto-immune ...

The term 'autophagy' was chosen to distinguish the lysosomal degradation, or 'eating' (phagy), of part of the cell's self (auto) from the ... and wortmannin (Wm) also inhibit class I ...

One of the therapeutic drugs for T2DM, dipeptidyl peptidase-4 (DPP-4) inhibitor ... residues are not auto-phosphorylated to activate insulin receptor substrate 1, which mediates downstream signaling ...

Glycolytic inhibitors significantly enhances the cytotoxicity induced by FLT3 tyrosine kinase inhibitor sorafenib. Importantly, such combination provides substantial therapeutic benefit in a ...

A national study seeking more effective treatment for deadly metaplastic breast cancer has identified two inhibitor drugs with the potential to interrupt disease progression.

F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have identified new benzimidazoles acting as serine/threonine-protein kinase SIK inhibitors reported to be useful for the treatment of rheumatoid ...

An Inventisbio Co. Ltd. and Inventisbio LLC patent discloses new phosphatidylinositol 3-kinase α (PI3Kα) inhibitors reported to be useful for the treatment of cancer, PIK3CA-related overgrowth ...

Their primary technology involves Polynucleotide Kinase 3′-Phosphatase (PNKP) inhibitors aimed at enhancing chemotherapy effectiveness by overcoming cancer cell resistance. The company is ...

Myeloid deficiency of the mitochondrial transacetylase tafazzin upregulates mtROS, disrupting UPR and calcium homeostasis, ...

Several clinical trials investigate the efficacy of GEM in combination with targeted drugs, including kinase inhibitors, but the experimental evidence for such rationale is often unclear. Here, we ...

Xiong has now discovered a key regulator that could be used to inhibit the overactivity of LRRK2. Xiong published these findings in Science Advances. LRRK2 has two enzyme "domains"—a kinase and ...

8 Zhang Y, Zou JY, Wang Z, Wang Y. Fruquintinib: a novel antivascular endothelial growth factor receptor tyrosine kinase inhibitor for the treatment of metastatic colorectal cancer. Cancer Manag Res.